Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KZR-616 in polymyositis and dermatomyositis
NCT04628936Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of zetomipzomib in polymyositis (PM) and dermatomyositis (DM), sponsored by Kezar Life Sciences. Primary endpoint: Total Improvement Score at 48 weeks. Started Nov 2020; status: completed.
02
Drugs
zetomipzomib
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04628936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628936.